- Previous Close
7.62 - Open
7.74 - Bid 7.68 x 1200
- Ask 7.90 x 900
- Day's Range
7.65 - 7.98 - 52 Week Range
5.26 - 75.20 - Volume
434,373 - Avg. Volume
1,391,030 - Market Cap (intraday)
430.709M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-18.00 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.80
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
www.ginkgobioworks.comRecent News: DNA
View More
Performance Overview: DNA
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNA
View MoreValuation Measures
Market Cap
430.71M
Enterprise Value
152.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.10
Price/Book (mrq)
0.52
Enterprise Value/Revenue
0.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.30%
Return on Equity (ttm)
-76.83%
Revenue (ttm)
184.34M
Net Income Avi to Common (ttm)
-897.68M
Diluted EPS (ttm)
-18.00
Balance Sheet and Cash Flow
Total Cash (mrq)
730.37M
Total Debt/Equity (mrq)
54.29%
Levered Free Cash Flow (ttm)
-167.4M
Research Analysis: DNA
View MoreCompany Insights: DNA
DNA does not have Company Insights